Veitl Felix, Eichinger Andreas, Mayrhofer Peter, Anneser Markus R, Testanera Mauricio, Rauscher Kilian, Lenz Matthias, Skerra Arne
Chair of Biological Chemistry, School of Life Sciences, Technical University of Munich, 85354, Freising, Germany.
Chembiochem. 2025 Jun 3;26(11):e202500102. doi: 10.1002/cbic.202500102. Epub 2025 Apr 7.
While protein A affinity chromatography is widely established for antibody purification, the acidic elution conditions often lead to protein aggregation and deamidation. Here, an alternative approach is described for the purification of antibodies utilizing an engineered binding protein based on the archaebacterial Sac7d scaffold in combination with light-controlled α-CD affinity chromatography (Excitography). Starting from a published affitin molecule, a monomeric protein version (C3A24) was engineered by substituting the unpaired thiol side chain Cys24 within the binding site by Ala, and, unexpectedly, its binding activity towards the human IgG1 Fc region was even improved (K = 76 nM). X-ray analysis of the cocrystallized C3A24 with a recombinant human Fc fragment revealed a 2:1 stoichiometry, with a binding site at the junction between the C2 and C3 domains. Interestingly, this binding site coincides with the ones of protein A, protein G, and the neonatal Fc receptor (FcRn). The affitin/Fc interaction is dominated by a network of hydrogen bonds, whereas, unpredicted by the initial affitin design, the two C-terminal Lys residues are also involved via a salt bridge and another hydrogen bond. Using the Azo-tagged C3A24, we purified clinically relevant antibodies from cell culture medium in a single step under physiological buffer conditions.
虽然蛋白A亲和层析在抗体纯化方面已被广泛应用,但酸性洗脱条件常常导致蛋白质聚集和脱酰胺化。在此,本文描述了一种利用基于古细菌Sac7d支架的工程化结合蛋白与光控α-环糊精亲和层析(激发层析)相结合来纯化抗体的替代方法。从已发表的亲和素分子出发,通过将结合位点内未配对的巯基侧链半胱氨酸24替换为丙氨酸,构建了一个单体蛋白版本(C3A24),出乎意料的是,其对人IgG1 Fc区域的结合活性甚至有所提高(K = 76 nM)。对共结晶的C3A24与重组人Fc片段进行X射线分析,结果显示其化学计量比为2:1,结合位点位于C2和C3结构域之间的连接处。有趣的是,该结合位点与蛋白A、蛋白G和新生儿Fc受体(FcRn)的结合位点重合。亲和素/Fc相互作用主要由氢键网络主导,然而,与最初的亲和素设计预测不同的是,两个C末端赖氨酸残基也通过盐桥和另一个氢键参与其中。使用偶氮标记的C3A24,我们在生理缓冲条件下通过一步从细胞培养基中纯化出了临床相关抗体。